Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242.
View in:
PubMed
subject areas
Animals
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Cell Proliferation
Cetuximab
Drug Resistance, Neoplasm
ErbB Receptors
Humans
Lung Neoplasms
Male
Mice
Mice, Nude
Phosphatidylinositol 3-Kinases
Proto-Oncogene Proteins c-akt
Receptor, ErbB-2
Receptor, ErbB-3
Signal Transduction
Xenograft Model Antitumor Assays
authors with profiles
Ravi Salgia